**TABLE 1** Operational changes during the COVID-19 pandemic for ALL patients treated in the Hematology Department of the Dr. José E. González University Hospital of the Universidad Autónoma de Nuevo León, Monterrey, México.

|  |  |
| --- | --- |
| ***Category*** | ***Operational Changes*** |
| **Hospital Areas** | § The main building is a 600-bed hospital designated for the treatment of non-COVID-19 cases.  § The second building with a 76-bed hospital was designated for suspected or confirmed COVID-19 patients.  § Only a single caregiver was allowed during the entire stay  § During hospitalization, patients and caregivers were requested to remain in their rooms and avoid external contact |
| **Clinical Staff** | § Staff rotation was reduced to a minimum and all non-medical on-site activities were suspended (educational, laboratory, or voluntary work)  § The totality of the specialized nursing staff in the outpatient clinic was maintained and the hours of attention were extended. |
| **Treatment protocol for leukemia patients with fever**  **Treatment** | * All patients were admitted to the hospital's COVID-19 area, where laboratory tests were performed: * SARS-CoV-2 PCR test * Complete blood count * Acute phase reactant tests * Blood cultures * Stable, non-neutropenic patients were discharged with symptom control medication and telephone follow-up. * Patients with any of the following symptoms were hospitalized in the COVID-19 area for further assessment and treatment. * Neutropenic (≤ 500) * Unstable * High transfusion requirements * Supplementary oxygen * History of poor adherence to treatment * All neutropenic patients started high-spectrum antibiotic therapy with Imipenem * Patients negative for SARS-Cov-2 were transferred to the first building within 48 hours. * It was decided not to modify the institutional chemotherapy regime\* * We recommended starting treatment for ALL <72h after the presentation to the center and <24h after diagnosis. * Toxicity delays were monitored every 72 hours * Monthly telemedicine follow-up of patients on surveillance * All non-urgent admissions and consultations were postponed. * SARS-Cov-2 positive patients in remission suspended chemotherapy for 14 days. * SARS-Cov-2 positive patients in induction to remission or reinduction due to relapse received chemotherapy regimen with escalating doses of Methotrexate and L-asparaginase every 10 days. |

\*=Each change in the protocol was discussed and documented by the medical team

COVID-19: coronavirus disease 2019

ALL: acute lymphoblastic leukemia

PCR: polymerase chain reaction